-
Study aim
-
Evaluation and therapeutic efficacy of Helicobacter pylori eradication protocol by adding each of the drugs simvastatin, probiotics and N-acetylcysteine (NAC)
-
Design
-
Individuals (162 patients) are divided into four groups of 42 in each group based on random permutations. Phase 2-3
-
Settings and conduct
-
Patients with positive helicobacter pylori infection in the gastroenterology clinic of Imam Hossein Hospital who meet the inclusion criteria.
After collecting demographic, clinical and medical records or previous treatments, patients will be randomly assigned to one of four intervention groups: 1) four drugs (metronidazole, amoxicillin, pentaprazole and bismuth, 2) four drugs with probiotics yasimvastatin.
or NAC for two weeks . Evaluation by stool antigen tests and Clinical signs one month after treatment
-
Participants/Inclusion and exclusion criteria
-
People over 18 years and under 65 years of age are non-pregnant and with positive stool or endoscopic antigen test for Helicobacter pylori without history of heart failure, kidney and liver failure, no diabetes, no active cancer, no drug and alcohol addiction, no history of receiving previous treatment and no recent history of gastrointestinal bleeding.
-
Intervention groups
-
After collecting baseline information including demographic characteristics, clinical manifestations, and previous medical or therapeutic records, patients were divided into four intervention groups: 1) The standard four-drug protocol receiving group (metronidazole 250 mg, amoxicillin 1000 mg, pentaprazole 40 mg and bismuth 120 mg) all twice a day, 2) the four-drug protocol receiving group with probiotics ( 250 mg daily), 3) four-drug protocol group with simvastatin (10 mg daily) and 4) four-drug protocol group with NAC (600 mg daily).
-
Main outcome variables
-
Comparison of Helicobacter pylori eradication in the study groups.